None
Quote | Taiwan Liposome Company Ltd. (NASDAQ:TLC)
Last: | $7 |
---|---|
Change Percent: | 0.0% |
Open: | $7 |
Close: | $7 |
High: | $7 |
Low: | $7 |
Volume: | 8,606 |
Last Trade Date Time: | 09/28/2021 11:27:03 am |
News | Taiwan Liposome Company Ltd. (NASDAQ:TLC)
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Sele...
Message Board Posts | Taiwan Liposome Company Ltd. (NASDAQ:TLC)
Subject | By | Source | When |
---|---|---|---|
#DDAmanda Chart on: $TLC | TraderStig | investorshub | 09/23/2021 1:27:29 AM |
$TLC READY $FOR SOME NEWS . | FROZENFLAME | investorshub | 11/16/2020 12:19:32 AM |
$$$TLC$$$ | FROZENFLAME | investorshub | 11/06/2020 5:35:11 PM |
https://ir.tlcbio.com/news-releases/news-release-details/tlc-announces-acceptanc | FROZENFLAME | investorshub | 11/03/2020 7:28:59 PM |
Nice close . | FROZENFLAME | investorshub | 11/02/2020 10:09:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Taiwan Liposome Company Ltd. Company Name:
TLC Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharma...
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Sele...